Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations

Authors:

Abstract
No abstract available
Funding Information
  • Mirati Therapeutics
  • Dana-Farber Cancer Institute
  • University of Alabama

This publication has 35 references indexed in Scilit: